Groundbreaking Drug Launches
Elamipretide (Forzinity)
Mechanism of Action: Cyclo-oxygenase 2 inhibitors; Serotonin 1B receptor agonists; Serotonin 1D receptor agonists Drug class: Small molecules Originator: Cornell University; Institut de recherches cliniques de Montreal
Developer: Stealth BioTherapeutics Indication: Barth syndrome Launched date: 4 December, 2025 (USA) Trial: TAZPOWER
Barth syndrome
Barth syndrome (BTHS) is a rare, serious X-linked genetic condition that mainly affects males and is marked by cardiomyopathy, skeletal muscle weakness, and neutropenia. Caused by mutations in the TAZ gene that disrupt mitochondrial energy production, the disorder can lead to recurrent infections, delayed growth, and an increased risk of heart failure.
Key Features
- Cardiomyopathy: An enlarged, weakened heart—often evident from infancy—that can progress to heart failure.
- Neutropenia: Reduced neutrophil levels, increasing susceptibility to recurrent infections such as pneumonia or oral ulcers.
- Skeletal Myopathy: Weakness of major muscle groups, leading to delayed motor development, early fatigue, and limited exercise tolerance.
- Growth Delay: Short stature during childhood, with many individuals experiencing notable catch-up growth after puberty.
- Distinctive Facial Characteristics: Features such as a round face, prominent cheeks, and large ears, particularly noticeable in early life.
Treatment challenges Treatment of Barth syndrome is challenging due to its rarity, multisystem involvement affecting the heart, immune system, and muscles, and the absence of curative therapies. Care is largely symptomatic and requires coordinated, multidisciplinary management of cardiomyopathy, neutropenia, and developmental concerns, while ongoing research explores targeted approaches such as elamipretide and gene therapy to address the underlying mitochondrial dysfunction.
Why is Elamipretide poised to make an impact in 2026?
Elamipretide (Forzinity) is an aromatic-cationic, mitochondria-targeting tetrapeptide developed by Stealth BioTherapeutics (formerly Stealth Peptides) for the treatment of primary mitochondrial myopathy associated with nuclear DNA (nDNA) mutations, Barth syndrome, and dry age-related macular degeneration. Forzinity (elamipretide) is emerging as a milestone therapy as the first FDA-approved treatment for Barth syndrome, receiving accelerated approval in September 2025. Its importance is expected to increase in 2026 as Stealth BioTherapeutics collaborates with the FDA on confirmatory studies, which could broaden pediatric access and strengthen its position in the evolving field of mitochondrial medicine.
While no single consensus revenue forecast is available, key market indicators outline its potential. Forzinity is priced at nearly $800,000 per patient annually, reflecting its use in an ultra-rare condition that affects an estimated one in a million males. Approximately 150 patients are identified in the U.S., with 230–250 cases reported globally, though the disorder remains significantly underdiagnosed. The overall Barth syndrome therapeutics market, valued at $147.4 million in 2025, is projected to grow substantially over the next decade, underscoring the long-term opportunity for Forzinity.
Regulatory milestones for Elamipretide
Registrational Trials
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Forzinity (elamipretide) injection as the first treatment for Barth syndrome in patients weighing at least 30 kg, supported by the efficacy and safety data from the TAZPOWER clinical trial.
TAZPOWER:
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Crossover Trial to Evaluate the Safety and Efficacy of Subcutaneous Injections of Elamipretide in Subjects With Genetically Confirmed Barth Syndrome Followed by Open-Label Treatment (NCT03098797).
“The first FDA-approved therapy for Barth syndrome was authorized based on the TAZPOWER study, which demonstrated improvements in knee muscle strength during long-term follow-up, despite early trials not meeting all primary functional endpoints.”